跳至主要内容
临床试验/NL-OMON41468
NL-OMON41468已完成3 期

The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation - Incomplete TUR and IL-2

Vrije Universiteit Medisch Centrum0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patients with the diagnosis multiple (< 10) resectable Ta(G1,2) or T1(G1,2) non-muscle invasive bladder carcinoma as diagnosed by pathological examination

排除标准

  • Excluded are patients with CIS, or a cancer type other than urothelial cell carcinoma, or with a second malignancy (except treated basal cell carcinoma of the skin), or a tumour in the prostatic urethra or in a diverticulum or in the upper urinary tract

研究者

相似试验